Clinical trial
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of…
NCT00234507 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00234507 |
|---|---|
| Title | Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm |
| Official title | Phase II, Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection, of Three Doses of Dysport (40 Units/Eye, 80 Units/Eye, and 120 Units/Eye) for the Treatment of Benign Essential… |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Blepharospasm |
| Intervention type | Biological |
| Interventions | Botulinum toxin type A |
| Enrollment | 120 |
| Start date | Jan 1, 2003 |
| Primary completion | May 25, 2004 |
| Completion | May 25, 2004 |
| First posted | Oct 7, 2005 |
| Last update posted | Jul 29, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: